GlassScriptPhysician profile
Fred C Foshee
NPI 1245421668
$2,742.78
in general payments reported to CMS, 2019-2025
22 companies · $268 in 2025
The $268 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.36 · 2020: $523 · 2021: $688 · 2022: $607 · 2023: $261 · 2024: $371 · 2025: $268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $868 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $868.17 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $728.55 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $529.24 | 2020-2023 | |
| Abbvie INC. | $220.83 | 2021-2025 | |
| Glaxosmithkline, LLC. | $203.10 | 2020-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $196.55 | 2019-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $180.66 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Amarin Pharma, INC. | $101.05 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $88.62 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $72.05 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.11 | 2019-2024 | Jardiance |
| Astellas Pharma US INC | $47.81 | 2021-2022 | |
| Amgen INC. | $39.96 | 2022-2024 | Repatha, Otezla |
| Sanofi-Aventis U.S. LLC | $39.80 | 2020-2021 | |
| Intra-Sana Laboratories | $35.00 | 2024-2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Xeris Pharmaceuticals, INC. | $34.52 | 2021-2025 | Gvoke Hypopen |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $31.60 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.65 | 2022 | |
| Sunovion Pharmaceuticals INC. | $27.81 | 2022 | |
| Axsome Therapeutics, INC. | $23.60 | 2025 | Auvelity |
| Janssen Biotech, INC. | $18.25 | 2021 | |
| Sumitomo Pharma America, INC. | $18.20 | 2023 | Gemtesa |
| Ascend Therapeutics US, LLC | $11.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fred Foshee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.